SynCore Biotechnology Co.,Ltd (TPEX:4192)

Taiwan · Delayed Price · Currency is TWD

19.60

+0.30 (1.55%)

Aug 4, 2026, 1:08 PM CST

-28.86% (1Y)

Market Cap	689.22M -28.9%
Revenue (ttm)	27.78M +14.1%
Net Income	-45.07M
EPS	-1.28
Shares Out	35.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,001
Open	19.00
Previous Close	19.30
Day's Range	18.05 - 19.60
52-Week Range	18.05 - 29.65
Beta	0.24
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About TPEX:4192

SynCore Biotechnology Co.,Ltd, engages in development and sale of healthy food, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04, ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2008

Employees 40

Stock Exchange Taipei Exchange

Ticker Symbol 4192

Full Company Profile

Financial Performance

In 2025, TPEX:4192's revenue was 27.04 million, an increase of 15.88% compared to the previous year's 23.34 million. Losses were -45.76 million, -15.71% less than in 2024.

Financial Statements